Accelerator Life Science Partners
VC Fund
Accelerator Life Science Partners is a VC fund focused on Health Care and Biotechnology. Accelerator Life Science Partners
- Total investments:
- 10
- Last investment:
- Lead investor:
- 80%
Last updated:
For AI agents: llms.txt
Industries Accelerator Life Science Partners invests in
Stages Accelerator Life Science Partners invests in
Countries Accelerator Life Science Partners invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Alice Chen
|
|||
Ian A.W. Howes
|
|||
David L. Pompliano
|
|||
David Pompliano
|
|||
David Schubert
|
|||
| See all 6 contacts → | |||
Investment Focus
Industry
- Health Care 4 (40%)
- Biotechnology 4 (40%)
- Neuroscience 2 (20%)
- Medical 1 (10%)
- Wellness 1 (10%)
Stage
- Series A 3 (30%)
- Pre-Seed 1 (10%)
- Series B 1 (10%)
- Funding Round 1 (10%)
Country
- United States 4 (40%)
- Singapore 1 (10%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Alice Chen
Executive Vice President
|
Executive Vice President | Total investments: 1 | Find email | |
|
Ian A.W. Howes
CFO
|
CFO | Total investments: 0 | Find email | |
|
David L. Pompliano
Operating Partner
|
Operating Partner | Total investments: 0 | Find email | |
|
David Pompliano
Operating Partner
|
Operating Partner | Total investments: 0 | Find email | |
|
David Schubert
Chief Operating Partner
|
Chief Operating Partner | Total investments: 1 | Find email | |
| See all 6 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Proniras
|
Proniras Corp is an operator of a biomedical company intended to develop drugs. The company's biomedical service has already demonstrated preclinical efficacy in treating nerve agent-induced seizures, as well as in studies of rodents exposed to the chemical weapon soman, which is more toxic than sarin gas, enabling medical researchers tocontinue their research work and discover drugs.It was founded in 2016 and is headquartered in Seattle, Washington. | $4.7M / Series B / Feb 01, 2024 | |
Automera
|
Automera focuses on a novel therapeutic methods to develop drugs. | $16M / Series A / Sep 26, 2023 | |
|
Automera
|
Automera focuses on a novel therapeutic methods to develop drugs. | $16M / Series A / Sep 26, 2023 | |
|
Automera
|
Automera focuses on a novel therapeutic methods to develop drugs. | $16M / Series A / Sep 26, 2023 | |
KayoThera
|
KayoThera is a biotechnology company developing therapeutics used to cure late-stage and metastatic cancers. Its programs work on inhibiting a key enzyme that is responsible for protecting the cancer cells and depleting regulatory T-cells that intends to cure hitherto incurable cancers and give hope to patients. The company's mission is todevelop the first-in-class immuno- and targeted therapies to drive cures in advanced cancersKayoThera was founded in 2019 and is headquartered in Princeton, New Jersey. | $5.2M / Series A / Jul 19, 2023 | |
|
KayoThera
|
KayoThera is a biotechnology company developing therapeutics used to cure late-stage and metastatic cancers. Its programs work on inhibiting a key enzyme that is responsible for protecting the cancer cells and depleting regulatory T-cells that intends to cure hitherto incurable cancers and give hope to patients. The company's mission is todevelop the first-in-class immuno- and targeted therapies to drive cures in advanced cancersKayoThera was founded in 2019 and is headquartered in Princeton, New Jersey. | $8M / Series A / Mar 16, 2022 | |
|
KayoThera
|
KayoThera is a biotechnology company developing therapeutics used to cure late-stage and metastatic cancers. Its programs work on inhibiting a key enzyme that is responsible for protecting the cancer cells and depleting regulatory T-cells that intends to cure hitherto incurable cancers and give hope to patients. The company's mission is todevelop the first-in-class immuno- and targeted therapies to drive cures in advanced cancersKayoThera was founded in 2019 and is headquartered in Princeton, New Jersey. | $8M / Series A / Mar 16, 2022 | |
Lydian Neurosciences
|
Lydian Neurosciences focusses on developing small molecules for the treatment of sleep disorders. | Pre-Seed / Jun 24, 2021 | |
Magnolia NeuroSciences
|
Magnolia Neurosciences aims to discover and develop proprietary, selective, and drug-like small molecule therapeutics for the prevention of neuronal cell death, thereby providing novel treatment options for patients suffering from neurodegeneration and related conditions. Magnolia Neurosciences Corporation, created to pursue technologies developedat The University of Texas MD Anderson Cancer Center’s Therapeutics Discovery Division and the Neurodegeneration Consortium (NDC), is a New York-based Accelerator Life Science Partner portfolio company. | $31M / Series A / Aug 13, 2018 | |
|
Proniras
|
Proniras Corp is an operator of a biomedical company intended to develop drugs. The company's biomedical service has already demonstrated preclinical efficacy in treating nerve agent-induced seizures, as well as in studies of rodents exposed to the chemical weapon soman, which is more toxic than sarin gas, enabling medical researchers tocontinue their research work and discover drugs.It was founded in 2016 and is headquartered in Seattle, Washington. | $4.3M / Aug 22, 2017 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Accelerator Life Science Partners invest in?
Accelerator Life Science Partners invests primarily in Health Care, Biotechnology and Neuroscience startups, most often at Series A and Pre-Seed stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Accelerator Life Science Partners?
Public channels for Accelerator Life Science Partners include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Accelerator Life Science Partners?
The team at Accelerator Life Science Partners includes Alice Chen (Executive Vice President), Ian A.W. Howes (CFO) and David L. Pompliano (Operating Partner), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
